HLDA-212
HLDA-212 (Compound 43) is a bifunctional small molecule targeting HaloTag-tagged protein (Target Protein, TP) and Aurora kinase A/B (AURKA/B, Effector Protein, EP) . HLDA-212 binds to TP and EP to form a stable ternary complex (TP:RIPTAC:EP), inhibiting the cell-survival function of EP and inducing apoptosis in TP-expressing cancer cells. HLDA-212 shows antiproliferative activity (GI50 of 0.011 μM) in 293_HFL cells. HLDA-212 is promising for research of cancers with high TP expression (such as prostate cancer and hematological malignancies) [1].
Product Specifications
CAS Number
3077339-88-6
UNSPSC
12352005
Target
Apoptosis; Aurora Kinase
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
Molecular Formula
C70H90BrFN8O19S
Molecular Weight
1478.47
References & Citations
[1]Ma Z, et al. RIPTACs: A groundbreaking approach to drug discovery. Drug Discov Today. 2023 Nov;28 (11) :103774.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
(1R,2R) - (1S,2S,3R,5S) -Pinanediol-N- (N-pyrazinylphenylalaninoyl) -1-aminopentyl-1-boronate
(1R,2R) - (1S,2S,3R,5S) -Pinanediol-N- (N-pyrazinylphenylalaninoyl) -1-aminopentyl-1-boronate
ARMCX3 (ALEX3, Armadillo Repeat-containing X-linked Protein 3, ARM Protein Lost in Epithelial Cancers on Chromosome X 3, DKFZp781N1954, KIAA0443, MGC12199, dJ545K15.2) (MaxLight 490)
Lentiviral human CCT5 shRNA (UAS) - Lentiviral human CCT5 shRNA (UAS) (25)